Document Type
Article
Publication Date
9-1-2026
Abstract
Despite the lack of evidence of a mechanism-based drug interaction, some professional organizations have advised caution coadministering apixaban and levetiracetam. Eligible patients taking apixaban with or without levetiracetam for any indication for at least 72 h were screened from the electronic medical records. Plasma samples from 77 patients were retrieved from salvaged clinical blood collections. Apixaban minimum and maximum concentrations (Cmin and Cmax) were compared using descriptive statistics in R. While the median Cmin and Cmax appear to be marginally elevated, there were no apparent differences relative to apixaban alone. These findings suggest no apparent interaction of levetiracetam and support the current lack of labeled warning of concomitant apixaban dosing.
Recommended Citation
Riley, Chazmyn; Lam, Kevin; Micale, Cristina; Thomson, Lynda; Stickle, Douglas F.; and Kraft, Walter K., "An Observational Study of the Effect of Concomitant Levetiracetam on Apixaban Concentrations in a Hospital Cohort" (2026). Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers. Paper 70.
https://jdc.jefferson.edu/ppcbfp/70
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Language
English
Included in
Chemical Actions and Uses Commons, Pharmacology Commons, Translational Medical Research Commons
Comments
This article is the author’s final published version in Clinical and Translational Science, Volume 19, Issue 9, 2026, Article number e70719.
The published version is available at https://doi.org/10.1111/cts.70719. Copyright © 2026 The Author(s).